RIGHTMINDER
29.3.2017 08:02:54 CEST | Business Wire | Press release
With the exponential growth of the aged care industry, cost and care issues are prevalent not only in the UK and Europe but globally. ConnectUs Life Pty Ltd, a specialist care-related services provider has launched RightMinder®, an app that leverages advancements in wearable technology and the increase in availability and use of affordable smartwatches. Coinciding with the release of Android Wear 2.0, RightMinder® caters to the elderly, those in need, pre-teens and Professional Carers. Available in multiple languages and in over 136 countries, RightMinder® delivers a patent-pending solution providing fall detection, first alert monitoring and alerts, GPS location reporting, and multiple first alert carer connections.
RightMinder® has been created to connect ‘wearers’ and ‘carers’. Ben Slater, ConnectUs Life CIO says, ”Our core focus is to ensure wearers maintain meaningful independence with an efficient, yet discreet safety and security alert system. Anyone can use RightMinder® without lock-in contracts, nor do they need expensive custom hardware.” Mr Slater says, “Our First Alert Carers are not only from the family & friends orientated network, but also paid professional Carers too.”
Whilst RightMinder® is specifically designed for Android smartwatches (for wearers), the First Alert and Fall Detection functionality is also available on the mobile phone itself, so anyone can use RightMinder® without requiring a smartwatch. However, RightMinder® strongly recommends using a smartwatch for safety and as a discreet alternative to “the big red emergency button” or pendant. Mr Slater says, “We are extremely encouraged by the acceptance of smartwatch technology amongst our focus groups. Wearers have embraced smartwatch technology when paired with the RightMinder® app. RightMinder® has proven to be very easy to use and manage, despite the underlying complexity of the algorithms utilised.”
RightMinder® wearers are securely connected to one or more carers who can then monitor battery life, location and access fast-touch call buttons. If a Wearer triggers a Fall Detection, or if they send an emergency First Alert, their carers all receive immediate notifications and emails to raise an emergency response. Carers then have the option to locate or call their wearers immediately. Additionally when battery life gets low, notifications are also sent to both wearer and carers.
RightMinder® also extends to people living with disabilities such as MS, dementia, brain trauma, epilepsy and for other high need individuals.
RightMinder® helps reduce the level of dependence on professional operators and on tax funded government assistance.
Contrary to the notion that technology can be complicated, RightMinder® is easy-to-use with a user-friendly interface that has been designed to benefit users who are wearers and carers. Alerting carers is now fast, simple and discreet for any RightMinder® wearer.
The convenience that comes with using the app, in addition to the affordability of the innovative concept, gives independence and empowerment to wearers and comfort to carers like never before, even if wearers and carers live countries apart.
RightMinder® aims for peace of mind without being front of mind.
RightMinder® is available on Google Play Store for Carers and Wearers and coming soon to the Apple App Store (for Carers).
For a full video of the app, please see https://www.youtube.com/watch?v=c2XF2YPabDc .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006424/en/
Contact:
RightMinder
Drew Steptoe, Joint MD and CEO.
+61 423 009 082
drew@connectus.life
or
Ben
Slater, Joint MD and CIO.
+61 433 773 585
ben@connectus.life
www.connectus.life
| www.rightminder.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom